Wasdell gets HPRA nod at its new EU headquarters

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JoeGough)
(Image: Getty/JoeGough)

Related tags: Wasdell, Ireland, Brexit, HPRA

The Wasdell Group’s new EU headquarters in Dundalk, Ireland is set to commence operations later this year as part of the company’s “proactive contingency plan” ahead of Brexit.

The Health Products Regulatory Authority (HPRA) in December 2018 inspected the Dundalk, Ireland-based facility and has since certified the company to conduct Qualified Person (QP) batch certification and release of pharmaceutical products to Europe.

The facility – following a €30m ($34m) investment in 2018​ – is expected to commence operations in spring 2019, ahead of which the company is launching a recruitment drive for several positions.

A range of services will be offered at the facility, including QP release, analytical testing, and distribution services.

Colin Newbould, director of regulatory affairs and QP services at Wasdell called the Dundalk facility an integral part of the company’s “proactive contingency plan”​ to secure the supply chain ahead of the UK’s exit from the European Union (EU) on March 29, 2019.

CEO Vincent Dunne said in a press release: “With almost 75% of our turnover being a result of export business and a growing customer base in both the Irish and US markets, Dundalk was a logical choice for our EU headquarters.

“The new facility will allow us to continue to act as a gateway to Europe for our British and North American customers.”

The company last year also invested​ £500K ($651.9K) into its new microbiological and analytical laboratory at its Newcastle, UK site. 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more